Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on fertility

Description of key information

There are no key reproductive toxicity data available for trimethoxy(octyl)silane (CAS 3069-40-7). In the available 90-day oral repeated dose toxicity study with trimethoxy(octyl)silane, conducted according to OECD Test Guideline 408 and in compliance with GLP (BSL Bioservice, 2020), no treatment-related effects were observed in the examined reproductive organs and tissues during macroscopic and histopathology examinations. In addition, no effects were noted on the thyroid hormone levels.


Effect on fertility: via oral route
Endpoint conclusion:
no study available
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

There are no key reproductive toxicity data available for trimethoxy(octyl)silane (CAS 3069-40-7). In the available 90-day oral repeated dose toxicity study with trimethoxy(octyl)silane, conducted according to OECD Test Guideline 408 and in compliance with GLP (BSL Bioservice, 2020), no treatment-related effects were observed in the examined reproductive organs and tissues during macroscopic and histopathology examinations. In addition, no effects were noted on the thyroid hormone levels.

In a combined repeated dose toxicity study with the reproduction/developmental toxicity screening test with trimethoxy(octyl)silane, conducted according to OECD Test Guideline 422 and in compliance with GLP, a NOAEL of 300 mg/kg bw/day was concluded for reproduction toxicity based on no effects on estrous cyclicity, litter data, litter weight data, precoital interval and duration of gestation, pre- and post-natal data, reproductive indices, pup survival data, anogenital distance and nipple retention, pup thyroid weight and thyroid hormone analysis in parental males and pups sacrificed on PND 13 and male sacrificed at the end of recovery period and pup external findings in all dose groups for which data could be obtained (Eurofins Munich / BSL Munich 2018). This study is included as supporting information but is not considered to be key due to certain methodological deficiencies, which are described in more detail in the IUCLID dataset.

Effects on developmental toxicity

Description of key information

In the prenatal developmental toxicity study, conducted according to OECD Test Guideline 414 and in compliance with GLP, the NOAEL for maternal toxicity was concluded to be 100 mg/kg bw/day based on statistically significant test item-related effects in maternal animals at the highest dose tested of 300 mg/kg bw/day. These effects included decrease in mean body weight gain and food consumption. The NOAEL for foetal toxicity was concluded to be at least 300 mg/kg bw/day based on no significant effect observed in any of the foetal developmental parameters (BSL Bioservice, 2021).

Link to relevant study records
Reference
Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
12 August 2020 to 28 October 2020
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Version / remarks:
adopted 25 June 2018
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Limit test:
no
Species:
rat
Strain:
Wistar
Remarks:
Crl: WI(Han) (Full Barrier)
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River, 97633 Sulzfeld, Germany
- Age at study initiation: 11-12 weeks old (females at arrival); 17-25 weeks old (males at start of pairing)
- Weight at study initiation: females: 193 - 251 g; males: 366 - 487 g
- Fasting period before study: no
- Housing: kept individually in IVC cages except during the pre-mating period when females were kept in groups of two animals and during mating period when two females were paired with one male.
- Diet (e.g. ad libitum): Altromin 1324 maintenance diet for rats and mice, ad libitum
- Water (e.g. ad libitum): tap water, sulphur acidified to a pH of approximately 2.8, ad libitum
- Acclimation period: at least 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3°C
- Humidity (%): 55 +/- 10 %
- Air changes (per hr): 10 x / hour
- Photoperiod (hrs dark / hrs light): 12 hours light, 12 hours dark

Route of administration:
oral: gavage
Vehicle:
corn oil
Remarks:
dried and de-acidified
Details on exposure:
PREPARATION OF DOSING SOLUTIONS: The test item was weighed into a tared glass vial on a suitable precision balance and the vehicle was added to give the appropriate final concentration of the test item (w/w). The formulation was alternately vortexed and/or stirred until visual homogeneity is achieved. After homogenization the formulation was overlaid with a protective gas to prevent instability caused by repeated contact of the test item formulation with air. Based on the results of stability testing, the test item formulations were prepared at least every 11 days as given by Eurofins Munich Study No. STUG7.59AA2169-3. The prepared formulation was stored protected from light and at -15 to -35°C.

VEHICLE
- Justification for use and choice of vehicle (if other than water): The vehicle was selected in consultation with the sponsor based on the test item’s characteristics.
- Concentration in vehicle: 0, 7.5, 25, 75 mg/mL
- Amount of vehicle (if gavage): 4 mL/kg bw
- Lot/batch no. (if required): MKCK6411
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Before beginning of the treatment period, formulation samples were prepared and analysed in order to obtain knowledge about stability and homogeneity of the test item in the selected vehicle. Prestart homogeneity investigation was included on the samples collected from various levels (top, middle and bottom) of high dose and low dose groups. As the test item was shown to be homogenous after 30 min without stirring samples were not collected during the study for the investigation of homogeneity. Samples were taken for substance concentration in the first and last week of the study for all doses.
Details on mating procedure:
- Impregnation procedure: cohoused
- M/F ratio per cage: 1:2 ratio
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm positive vaginal smears referred to as day 0 of pregnancy
Duration of treatment / exposure:
from gestation day (GD) 5 to gestation day (GD) 19
Frequency of treatment:
daily
Duration of test:
20 days
Dose / conc.:
0 mg/kg bw/day (actual dose received)
Remarks:
control group
Dose / conc.:
30 mg/kg bw/day (actual dose received)
Remarks:
low dose (LD)
Dose / conc.:
100 mg/kg bw/day (actual dose received)
Remarks:
middle dose (MD)
Dose / conc.:
300 mg/kg bw/day (actual dose received)
Remarks:
high dose (HD)
No. of animals per sex per dose:
22-23 females per group
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: In consultation with the sponsor, based on a dose range finding study as well as an OECD 422 study.
In the 14-day dose range finding study, male and female Wistar rats were treated for 14 consecutive days at dose levels of 100, 300, and 1000 mg/kg bw/day or 600 mg/kg bw/day, respectively. Test item-related mortality occurred in 2/3 males and 3/3 females of the HD group (1000 mg/kg bw/day). Subsequently, the HD was reduced to 600 mg/kg bw/day on study day 12. Clinical findings such as paresis, ataxia, apathy, reduced spontaneous activity, wasp waist, abnormal breathing, dehydration, hypothermia, and chromodacryorrhea were observed at 1000/600 mg/kg bw/day. The animals of the MD (300 mg/kg bw/day) and LD (100 mg/kg bw/day) did not show any mortality or clinical signs. No toxic effects of the test item were observed in the haematology and clinical biochemistry as well as on organ weights. There were no macroscopic abnormalities at necropsy.
In the OECD 422 study, male and female Wistar rats were treated at dose levels of 100 (LD), 300/200 (MD), and 600/400 (HD) mg/kg bw/day. Test item-related mortality occurred in 1 male and 5 females at a dose of 600 mg/kg bw/day (HD and HD recovery). After a dose reduction to 400 mg/kg bw/day, additional 4 males and 10 females were sacrificed in a moribund condition. At the MD dose of 300 mg/kg bw/day, test item-related mortality occurred in 3 females and even after a dose reduction to 200 mg/kg bw/day additional 4 females were euthanized in a moribund condition. Already within the first 15 days of treatment, which is a duration of daily dosing similar to the one applied in the current OECD 414 study, test-item related mortality occurred in 5 males and 10 females of the HD/HD recovery (600 or 400 mg/kg) and in 1 female of the MD (300 mg/kg) groups.
Animals sacrificed in a moribund condition or animals at their terminal sacrifice from the MD, HD and HD recovery groups, mainly displayed test item related clinical signs like piloerection, reduced spontaneous activity, abdominal breathing, half eyelid closure, hypotonia, altered locomotion associated to general weakness, reduced grip strength, hunched posture and hypothermia. However, there were no effects on estrous cyclicity, litter data, litter weight data, precoital interval and duration of gestation, pre- and post-natal data, reproductive indices, pup survival data, anogenital distance and nipple retention, pup thyroid weight as well as thyroid hormone levels in parental males, pups sacrificed on PND 13 and males sacrificed at the end of their recovery period, and pup external findings in all groups with available data. For the current study, the highest dose level was chosen with the aim of inducing toxic effects, but not death or severe suffering. Therefore, a dose of 300 mg/kg bw/day was chosen as high dose. A descending sequence of dose levels was selected with an aim to demonstrate any dose-related responses and to identify a NOAEL.

- Rationale for animal assignment (if not random): random
Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: general clinical observations were made once per day; twice daily all animals were observed for morbidity and mortality except on weekends and public holidays when observations were made once daily;
- Cage side observations included: Clinical observations included spontaneous activity, lethargy, recumbent position, convulsions, tremors, apnoea, asphyxia, vocalisation, diarrhoea, changes in the skin and fur, eyes and mucous membranes (salivation, discharge), piloerection and pupil size. Changes in gait, posture, response to handling as well as the presence of clonic or tonic movements, stereotypes or bizarre behaviour were recorded.

BODY WEIGHT: Yes
- Time schedule for examinations: The sperm positive females were weighed on GDs 0, 5, 8, 11, 14, 17 and 20.

FOOD CONSUMPTION: Yes
- Time schedule: Food consumption of sperm positive females was measured on GDs 5, 8, 11, 14, 17 and 20.

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 20
- Organs examined: macroscopic examination of structural abnormalities or pathological changes which may have influenced the pregnancy; uteri; gravid uterus with the cervix was weighed; thyroid/parathyroid glands were weighed; a full histopathology was carried out on the preserved thyroid/parathyroid glands.

OTHER: Thyroid hormones
- Blood samples were collected prior to sacrifice for thyroid hormone (T3, T4, TSH) analysis.
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
Fetal examinations:
- External examinations: Yes: [all per litter]
- Soft tissue examinations: Yes: [half per litter]
- Skeletal examinations: Yes: [half per litter]
- Head examinations: Yes: [half per litter]
- Other: anogenital distance; foetal weight; examination of reproductive tract; external foetal sex was compared to gonadal sex; testicular descent/cryptorchidism was examined.
Statistics:
A statistical assessment of the results of the body weight and food consumption was performed by comparing values of dosed animals with control animals using a one-way ANOVA and a post-hoc Dunnett Test. Results of absolute and relative organ weights, thyroid hormones and foetal evaluation parameters like external, visceral, craniofacial and skeletal parameters were statistically analysed by comparing values of dosed with control animals using either a parametric one-way ANOVA and a post-hoc Dunnett Test or a non-parametric Kruskal-Wallis Test and a post-hoc Dunn’s Test, based on the results of homogeneity and normality tests. The statistics were performed with GraphPad Prism V.6.01 software or Ascentos 1.3.4 software (p<0.05 is considered as statistically significant).
Historical control data:
See attached historical control data tables.
Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
Clinical signs such as animals displaying hairless area or slight diarrhoea were considered incidental by nature and not test-item related.
Slightly increased salivation, moving the bedding were occasionally observed in single females of the high dose group, and several high dose dose group animals occasionally showed slight piloerection and slightly to moderately reduced spontaneous activity towards the end of the treatment period. These mild clinical signs were considered as signs of general discomfort of the animals due to oral administration or local reactions of the test item and were therefore assessed as test item-related but not indicative of systemic toxicity.
Mortality:
no mortality observed
Description (incidence):
No test item-related mortality was observed during the study period and all females survived until the end of the study.
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
The high dose group females showed moderately lower body weight gain when compared to the values of the control group. This difference was statistically significant on GDs 17-20 and for the total weight gained over the whole treatment period (GDs 5-20). This result was also reflected by the statistically significantly reduced mean carcass weight and the statistically significantly lower mean net weight change (= carcass weight – body weight from GD0) in high dose females compared to control females.
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Description (incidence and severity):
The observed test item-related effect on the body weight and body weight gain of the HD females was reflected by the statistically significantly lower food consumption of high dose females on GDs 17-20 and over the whole treatment period of GDs. 5-20. This effect was considered to be test item-related.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
no effects observed
Description (incidence and severity):
No statistically significant differences in uterine weight data were observed between the control group and the treatment groups.
There was no statistically significant or toxicologically relevant effect on the absolute and relative (to body weight) weights of post-fixed thyroid/parathyroids of the dose groups when compared to controls.
Gross pathological findings:
no effects observed
Description (incidence and severity):
No test item-related macroscopic findings were observed at necropsy. Animal no. 34 of the LD group showed a cyst at the ovaries and animal no. 50 of the MD group showed an abnormal content (gelatinous, brown) in the vagina, which were considered to be incidental.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
no effects observed
Description (incidence and severity):
There were no gross lesions or histology changes in the thyroid glands that could be related to treatment with the test item.
Histopathological findings: neoplastic:
no effects observed
Other effects:
no effects observed
Description (incidence and severity):
No statistically significant or toxicologically relevant effect was observed on group mean T3, T4 and TSH hormone levels of terminally sacrificed females. The values were comparable to those of controls.
Number of abortions:
no effects observed
Description (incidence and severity):
No female showed signs of abortion or premature delivery prior to the scheduled sacrifice.
Pre- and post-implantation loss:
no effects observed
Description (incidence and severity):
Treatment with the test item had no toxicologically relevant effect on prenatal data including the number of corpora lutea, implantation sites, living foetuses, early resorptions and late resorption and pre- and post-implantation loss when comparing test item-treated groups to the control group.
Total litter losses by resorption:
no effects observed
Early or late resorptions:
no effects observed
Description (incidence and severity):
Treatment with the test item had no toxicologically relevant effect on prenatal data including the number of corpora lutea, implantation sites, living foetuses, early resorptions and late resorption and pre- and post-implantation loss when comparing test item-treated groups to the control group.
Dead fetuses:
no effects observed
Description (incidence and severity):
Dead or malformed foetuses were not observed in any of the groups.
Changes in pregnancy duration:
no effects observed
Changes in number of pregnant:
no effects observed
Description (incidence and severity):
Successful mating resulted in 20/23 pregnancies in the control group, 23/23 pregnancies in the LD group, 20/22 pregnancies in the MD group and 21/22 pregnancies in the HD group. No female showed signs of abortion or premature delivery prior to the scheduled sacrifice.
Other effects:
not specified
Key result
Dose descriptor:
NOAEL
Remarks:
General toxicity
Effect level:
100 mg/kg bw/day (actual dose received)
Based on:
test mat.
Basis for effect level:
body weight and weight gain
food consumption and compound intake
Key result
Abnormalities:
effects observed, treatment-related
Localisation:
other: reduced mean body weight gain and mean food consumption
Fetal body weight changes:
no effects observed
Description (incidence and severity):
Despite the lower body weight and body weight gain of the HD females, the mean foetal weight was comparable between the treatment and control groups.

Mean male and mean female foetal weight was slightly, but statistically significantly higher in litters of the LD females compared to control. As the mean male and mean female foetal weight of MD and HD groups were comparable to values of the control group, the effect was not considered to be test item-related.
Reduction in number of live offspring:
no effects observed
Description (incidence and severity):
No statistically significant effect was observed on number of male and female foetuses per pregnant female and on the sex ratio of foetuses.
Changes in sex ratio:
no effects observed
Description (incidence and severity):
No statistically significant effect was observed on number of male and female foetuses per pregnant female and on the sex ratio of foetuses.
Changes in litter size and weights:
not examined
Changes in postnatal survival:
not examined
External malformations:
no effects observed
Description (incidence and severity):
There were no test item-related external abnormalities observed in any of the foetuses of treated groups.

One MD foetus of dam no. 64 was observed with a hyperflexion of the right hindlimb. As all other foetuses were without findings, this was considered to be incidental.
Skeletal malformations:
effects observed, non-treatment-related
Description (incidence and severity):
As usual for foetuses at the stage of GD 20, skeletal examination of the Alizarin red-stained foetuses revealed a range of findings in several bones of several litters in all groups including control. Mainly bones of the skull, sternum, limbs, and vertebra and ribs were affected by variations in the status of expected ossification in terms of incomplete ossification, unossification, irregular ossification or increased ossification throughout all groups. However, there were only statistically significantly more litters affected in the MD group for the finding “incomplete ossification of the frontal skull”. As there was no incomplete ossification of the frontal skull observed for foetuses of the HD group, there was no dose-dependency and the findings were therefore considered to be incidence in nature.
Visceral malformations:
effects observed, non-treatment-related
Description (incidence and severity):
Internal observation of the foetal viscera by free hand microdissection technique revealed a range of visceral findings in all groups including the control group.

Statistically significantly higher litter incidences for a supernumerary liver lobe were found in the HD group compared to control. However, these results were within the historical control data and, therefore, not considered as adverse. All other visceral findings observed in the dose groups were at frequencies generally comparable to or in some cases slightly higher or lower in frequency compared to controls. As the observed findings were either minor variations and/or due to a lack of dose dependency and consistency, no toxicological significance can be attributed to these findings and they were considered to be spontaneous in nature.
Other effects:
effects observed, non-treatment-related
Description (incidence and severity):
Craniofacial examination by razor blade serial sectioning technique revealed a range of findings in all dose groups at similar frequencies or in some cases in slightly lower or higher frequency than in litters of the control group. A statistically significantly higher litter incidence was not observed. Thus, none of the craniofacial findings were considered to be test item-related, but incidental in nature.
Key result
Dose descriptor:
NOAEL
Effect level:
>= 300 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male/female
Remarks on result:
not determinable due to absence of adverse toxic effects
Key result
Abnormalities:
no effects observed
Key result
Developmental effects observed:
no
Conclusions:
In the prenatal developmental toxicity study, conducted according to OECD Test Guideline 414 and in compliance with GLP, the NOAEL for maternal toxicity was concluded to be 100 mg/kg bw/day based on statistically significant test item-related effects in maternal animals at the highest dose tested of 300 mg/kg bw/day including decreased mean body weight, body weight gain and food consumption. The NOAEL for foetal toxicity was concluded to be at least 300 mg/kg bw/day based on no significant effect observed in any of the foetal developmental parameters.
Effect on developmental toxicity: via oral route
Endpoint conclusion:
no adverse effect observed
Species:
rat
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available
Additional information

In the key prenatal developmental toxicity study conducted according to OECD Test Guideline 414 and in compliance with GLP, pregnant female Wistar rats were exposed to trimethoxyoctylsilane (CAS RN 3069-40-7) by oral gavage at dose levels of 30, 100, 300 mg/kg bw/day, from gestation day 5 to 19. During the period of administration, the animals were observed precisely each day for signs of toxicity and mortality. Body weight and food consumption were measured on Gestation Day (GD) 0, 5, 8, 11, 14, 17 and 20. All female animals were sacrificed on the respective GD 20.

Following the gross necropsy, the uteri and ovaries were removed, weighed and examined for number of implantations, resorptions (early and late), live and dead foetuses. Foetuses were identified by using numbered plates, sexed and weighed. All foetuses were observed for external abnormalities, half of the foetuses for visceral and craniofacial abnormalities and the remaining half of the litter was observed for skeletal abnormalities (max. 20 litters). The uteri of the non-pregnant females were processed with 10 % ammonium sulphide solution and checked for the early embryonic deaths. Thyroid/parathyroid glands from all dams were preserved. The weight of thyroid/parathyroid glands was measured after fixation. Blood samples were assessed for serum levels for thyroid hormones.A histopathological evaluation of the preserved thyroid/parathyroid glands was performed.

No test item-related mortality was observed during the treatment period and all females survived until scheduled sacrifice.

Clinical signs such as moving the bedding, increased salivation, reduced spontaneous activity and piloerection, only observed in females of the High Dose (HD) group, were considered as signs of general discomfort of the animals due to oral administration or local reactions of the test item and were therefore assessed as test item-related.

There was a test item-related effect on the mean body weight, mean body weight gain, mean carcass weight and mean net weight change. All these values were statistically significantly reduced in the HD group when compared to controls. As there was a trend towards a slightly lower body weight gain in Low Dose (LD) and Middle Dose (MD) groups, the effect seemed to be dose-dependent. The observed test item-related effect on the body weight and body weight gain of the HD females was reflected by the statistically significantly lower food consumption of HD females. This effect was considered to be test item-related. There were no or only slight effects on food consumption in LD and MD females when compared to control females. Treatment with the test item had no toxicologically relevant effect on mean uterine weights, on prenatal data and on litter data including the number of corpora lutea, implantation sites, living foetuses, early resorptions and late resorption and pre- and post-implantation loss when comparing test item-treated groups to the control group. No statistically significant or toxicologically relevant effect was observed on group mean T3, T4 and TSH hormone levels, as well as on post-fixed absolute and relative (to body weight) thyroid/parathyroid weights in the dose groups when compared with the control values. No test item-related macroscopic findings at necropsy and no histopathological changes of the thyroid glands were observed. There were no test item-related changes in anogenital distance, external abnormalities, visceral, craniofacial or skeletal findings observed in any of the foetuses of treated groups. Thus, the NOAEL for maternal toxicity is considered to be 100 mg/kg bw/day and the NOAEL for foetal toxicity is considered to be at least 300 mg/kg bw/day in this study (BSL Bioservice, 2021).

In the combined repeated dose toxicity study with the reproduction/developmental toxicity screening test with trimethoxy(octyl)silane, conducted according to OECD Test Guideline 422 and in compliance with GLP, a NOAEL of 300 mg/kg bw/day was concluded for developmental toxicity based on no effects on litter data, litter weight data, pup survival data, anogenital distance and nipple retention, pup thyroid weight and thyroid hormone analysis and pup external findings in all dose groups for which data could be obtained (Eurofins Munich / BSL Munich 2018). This study is included as supporting information but is not considered to be key due to certain methodological deficiencies, which are described in more detail in the IUCLID dataset.

Justification for classification or non-classification

Based on the available data, trimethoxy(octyl)silane is not classified for adverse effects to reproduction or development according to Regulation (EC) No 1272/2008.

Additional information